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Summary
AIMS OF THE STUDY: Failure to publish publicly funded
research represents a waste of scarce research resources
across medical disciplines and countries. In Switzerland,
about 40% of randomised clinical trials (RCTs) supported
by the Swiss National Science Foundation (SNSF) were
not published. We aimed to describe funding character-
istics of published and unpublished RCTs supported by
the SNSF, to quantify the amount of money spent for un-
published studies, and to compare our results to a similar
study performed in the UK.
METHODS: We established a retrospective cohort of
RCTs funded by the SNSF up to 2015. For each RCT
proposal, two investigators independently identified cor-
responding publications in electronic databases and trial
registries. Teams of two investigators independently ex-
tracted details from the original SNSF proposal and, if
available, from trial registries or publications. In addition,
we surveyed principal investigators about trial costs and
additional sources of funding.
RESULTS: We included 101 RCTs supported by the SNSF
between 1986 and 2015. Most were single-centre RCTs
with a median of 138 participants (interquartile range [IQR]
76–400). Overall, 67 (67%) principal investigators re-
sponded to our main survey questions. Median total costs
per RCT were CHF 428 000 (IQR 282 000–900 000) of
which the SNSF provided a median CHF 222 000 (67%
of total costs, IQR 40–80%). Most investigators (70%)
mentioned additional funding, mainly from their own insti-
tution or private foundations. A total of CHF 6.7 million
was granted to RCTs that remained unpublished. Funding
characteristics were similar to publicly funded trials in the
UK.
CONCLUSIONS: A third of the total SNSF grant sum
spent on healthcare RCTs between 1986 and 2015 did not
result in peer-reviewed scientific publications. New SNSF
grant schemes might improve publication outcomes but
their effectiveness needs to be evaluated.
Key words: randomised clinical trials, clinical trial costs,
early termination of clinical trials, non-publication, Swiss
National Science Foundation
Introduction
Randomised clinical trials (RCTs) are the gold standard for
assesing healthcare interventions and a cornerstone of ev-
idence-based medicine [1, 2]. Over the last decade, new
regulations and guidelines for RCTs have been published,
including initiatives to better protect research participants,
improve trial methodology and harmonise research across
countries [3–5]. These initiatives may have increased re-
search quality, but also increased trial complexity and cost.
An estimated USD 99.6 billion was spent on biomedical
research by the public sector worldwide in 2012 [6]. Fund-
ing in biomedical research has more than doubled from
USD 37.1 billion in 1994 to USD 94.3 billion in 2003, and
it has been estimated that clinical trial research costs are
increasing by 7.5% per year above the rate of inflation [4,
7, 8]. Most clinical research is funded by industry (near-
ly 75% of US trials in 2000) [9]. Public-sector funded re-
search has increased over the past 10 years. In 2012, it
accounted for 37% of the global expenditure on biomed-
ical research [6]. A UK study analysed 122 RCTs fund-
ed by two major public healthcare sponsors between 1994
and 2002. Grant sum per participant ranged from GBP 16
(CHF 36) up to GBP 4522 (CHF 10 245) with a median of
GBP 641 (CHF 1452) [10].
At the same time, a substantial amount of public research
money is wasted because results of RCTs (or lessons
learned from discontinued RCTs) are not published.
Across medical disciplines and countries, the proportion of
unpublished trials is high and ranges between 30 and 60%
[11]. Expressing the resulting waste in monetary terms is
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difficult because data on funding characteristics of unpub-
lished RCTs are rarely available.
In a previous publication, we showed that 26 out of 101
(25%) RCTs supported by the Swiss National Science
Foundation (SNSF) were prematurely discontinued owing
to poor recruitment of study participants and 40% were not
published in a peer-reviewed scientific journal [12]. In the
present article we complement our findings with the fund-
ing characteristics of these 101 SNSF-supported RCTs. We
aimed to describe funding characteristics of published and
unpublished RCTs supported by the SNSF, to quantify the
amount of money spent for unpublished studies, and to
compare our results with a similar study performed in the
UK.
Materials and methods
Ethics approval
None was necessary because this study examined propos-
als approved by the Swiss National Science Foundation
and corresponding publications. Patients or patient data
were not involved.
Study design and data source
We established a retrospective cohort of SNSF-supported
RCTs for which recruitment and funding had ended in
2015 or earlier. We systematically searched titles and ab-
stracts provided on the SNSF’s p3 research database
(p3.snf.ch), which contains all research projects that the
SNSF approved and supported fully or partially. We ex-
cluded RCTs that were supported through personal grants
and that were carried out exclusively outside Switzerland
(i.e., SNSF mobility grants), RCTs that were never started,
and RCTs for which recruitment or funding was still on-
going at the time of the cut-off date (30 April 2015). The
search strategy included synonyms for “randomisation”
and “trial” and was limited to human healthcare categories
using the database’s “advanced search” option. (appendix
1).
For each eligible RCT, two methodologically trained in-
vestigators independently searched corresponding publica-
tions through information available in the SNSF’s p3 re-
search database, electronic databases (Medline, Embase,
Cochrane Central Register of Controlled Trials, Google
Scholar), and trial registries, using relevant keywords for
study design, population, interventions, and outcome if ap-
plicable. Furthermore, we screened personal websites of
principal investigators and co-investigators, and reference
lists of related articles. In addition, we approached all prin-
cipal investigators of included RCTs using an online ques-
tionnaire. We asked investigators for information about
funding characteristics (additional funding sources, esti-
mation of overall cost of their trial, estimation of percent-
age of SNSF support on the whole trial) and completion/
publication status of their trial, including the reason for dis-
continuation. If a principal investigator did not respond,
we sent several reminders by email, or a paper version of
the questionnaire by regular mail, and eventually tried to
call the investigator by telephone or approach a co-inves-
tigator. Sixty-seven of 101 investigators responded to all
of the following questions: “Please estimate the total costs
of the trial in CHF,” “Please estimate the proportion of to-
tal costs covered by the SNSF grant(s) in %,” and “If not
100% funding by the SNSF, please specify the sources of
additional funding.” Consequently, the overall minimum
response rate was 67%.
Data extraction
After data extractors signed appropriate confidentiality
statements, the SNSF granted access to its proposals. In
teams of two, data extractors trained in trial methodology
extracted data from trial proposals and, if available, from
corresponding publications independently and in duplicate.
Disagreements were resolved by discussion and consensus.
We used a password-protected web-based data extraction
tool (www.squiekero.org) that included a detailed manual
with instructions for each variable of interest.
Statistical analysis
We describe categorical variables as frequencies and per-
centages and continuous variables as medians and in-
terquartile ranges (IQRs). We used complete case analysis.
The SNSF’s p3 research database includes the approved
grant sum per proposal but not per study. Some proposals
combined RCTs with other studies such as pilot phases
or observational studies. To account for this, we stratified
the descriptive analyses by “SNSF grant proposal included
a RCT and other projects” vs “SNSF grant proposal in-
cluded one RCT only”. We were specifically interested in
the latter proposals for which we knew that the total grant
sum was allocated to the RCT. For SNSF grant proposals
that included several projects, we were not able to reliably
extract the amount of grant sum specifically used for the
RCT.
Comparison with similar data from the UK
Our systematic review of the literature found only one
comparable study that allowed us to extrapolate our re-
sults: a UK study that included RCTs supported by the
Medical Research Council (MRC) or the Health Technol-
ogy Assessment (HTA) programme from 1994–2002 [10].
To compare grant sums we (a) included SNSF-supported
RCT proposals that comprised one RCT only and (b) in-
cluded only SNSF-supported RCTs that started between
1994 and 2002. We used an exchange rate dating back to
April 2006 (1 GBP = 2.265 CHF) when the UK study was
published.
Results
Trial selection and characteristics of included trials
The search of SNSF’s p3 research database yielded 455
proposals, of which a total of 101 were eligible healthcare
RCTs, conducted between 1986 and 2015 (fig. 1). Twenty-
four proposals included other projects in addition to the
RCT. The median study size was 138 (interquartile range
[IQR] 76–400), and the median planned duration of re-
cruitment was 14 months (IQR 12–21 months). Most RCTs
were single-centre, parallel-group trials testing a medica-
tion or behavioural intervention in adults. Only 53% were
published in a peer-reviewed scientific journal and 30%
were prematurely discontinued owing to poor recruitment
of study participants. Of the 52 trials approved after the
ICMJE recommendation to prospectively register all RCTs
(i.e., in 2005 or later) [13], only 40 (77%) were registered
in a trial registry (table 1).
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Funding characteristics of included trials
Table 2 summarises the funding characteristics of the in-
cluded RCTs. Investigator-initiated RCTs received a medi-
an total of CHF 222 000 (IQR 166 000–276 000) from the
SNSF, with a median of CHF 1600 (IQR 600–3000) per
planned participant. According to investigators’ statements
in the survey, the median total cost of RCTs was CHF
428 000 (IQR CHF 282 000–900 000). The SNSF grant
sum covered a median of 67% (IQR 40–80%) of the total
trial cost. Seventy-four investigators responded to the spe-
cific survey question on whether additional funding was
Figure 1: Trial inclusion and exclusion
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obtained. Fifty-two (70%) mentioned additional funding,
mainly from their own institution or private foundations.
SNSF grant sum stratified by publication status
In a previous publication we reported on discontinuation
and nonpublication of these 101 SNSF-supported RCTs
[12]. For the analysis reported here, we limited our sample
to the SNSF grant proposals that included one RCT only,
resulting in a total of 74 eligible RCTs (fig. 1) and stratified
the data by publication status. Table 3 summarises char-
acteristics of the subsample of 74 RCTs. We identified
all peer-reviewed publications through searching electron-
ic databases with indexed publications. The search of trial
registries did not yield any additional publications. Table 4
shows that CHF 6.7 million out of CHF 20 477 189 (33%)
of SNSF grant sum spent over the last three decades for
grant proposals including one RCT only did not result in a
peer-reviewed scientific publication.
Table 1: Baseline characteristics of randomised clinical trials supported by the Swiss National Science Foundation.
All (n = 101)Characteristic
SNSF grant proposal included
one RCT only
(n = 74)
n (%)
SNSF grant proposal included a RCT
and other projects*
(n = 27)
n (%)
Age group of study population
Adults ≥18 to ≤60 yrs 65 (87) 23 (85)
Children <18 yrs 6 (8) 2 (7)
Elderly >60 yrs 3 (4) 2 (7)
Study population
Patients (suffering from disease or at risk for disease) 71 (96) 26 (96)
Healthy volunteers 3 (4) 1 (4)
Type of intervention
Behavioural intervention 26 (35) 10 (37)
Medication 22 (30) 11 (41)
Rehabilitation 9 (12) 2 (7)
Other† 9 (12) 3 (11)
Surgical 6 (8) 1 (4)
Diagnostic test 2 (3) 0 (0)
Planned centres
Single-centre 39 (53) 15 (56)
Multicentre national 25 (34) 9 (33)
Multicentre international 10 (13) 3 (11)
Planned sample size, median (IQR) 138 (76–400) 55 (36–125)‡
Trial design
Parallel 64 (86) 21 (78)
Cross-over 5 (7) 5 (18)
Factorial 4 (5) 1 (4)
Unclear 1 (1) 0 (0)
Pilot study planned 5 (7) 5 (19)
Pilot study conducted 0 (0) 1 (4)
Planned duration of recruitment, in months, median (IQR) 14 (12–21)§ 12 (8–21)¶
Completion status
Completed 49 (66) 20 (74)
Discontinued owing to slow recruitment 22 (30) 4 (15)
Discontinued for other reasons 0 (0) 0 (0)
Unclear 3 (4) 3 (11)
Publication status
Peer-reviewed scientific publication 39 (53) 14 (52)
Not published at all 13 (18) 6 (22)
Conference abstract only 11 (14) 1 (4)
Brief report or letter to editor only 2 (3) 1 (4)
Book chapter only 0 (0) 1 (4)
Status unclear** 9 (12) 4 (14)
Trial registration
% of trials that started before 2005 and were registered 36% (8/22) 27% (3/11)
% of trials that started in/after 2005 and were registered 77% (40/52) 69% (11/16)
IQR = interquartile range; RCT = randomised clinical trial; SNSF = Swiss National Science Foundation * We assumed that the data provided in the grant proposal qre associated
with the main RCT and not to the other project included in the same proposal (e.g., pilot/feasibility studies, observational studies). † Includes for example RCTs testing a treatment
algorithm or light therapy, etc. ‡ 1 missing datapoint for planned sample size due to poor quality of the study proposal or publication § 13 missing data for planned duration of
recruitment due to poor quality of the study proposal or publication ¶ 8 missing data for planned duration of recruitment due to poor quality of the study proposal or publication **
Follow-up ongoing (n =3 in first stratum and n = 1 in second strauma) or manuscript still in preparation up to 5 years after end of study (n = 6 in first stratum and n = 3 in second
stratum)
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Comparison with the UK trial cohort
McDonald et al. reported that grant sums ranged from GBP
6 (CHF 36) to GBP 4522 (CHF 10 245) per participant,
with a median of GBP 641 (CHF 1452) per participant.
Twenty-nine percent of the RCTs had more than GBP 1000
(CHF 2270) per participant available, which the authors
considered a sufficient level of funding.
To enhance the comparability of this exploratory analysis,
we restricted the sample to the 14 proposals that included
one RCT only and were started between 1994 and 2002
(fig. 1). The SNSF grant sum per RCT was similar to that
of the MRC and HTA programme in the UK, with a median
of CHF 1303 per participant and 3 of the 14 RCTs (21%)
receiving more than the amount per participant deemed
sufficient in the UK (table 5).
Discussion
Summary of findings
In the last three decades, SNSF-supported RCTs were
granted, on average, CHF 222 000, covering 67% of the
estimated total trial costs. Most applicants mentioned ad-
ditional funding from their own institution or private foun-
dations. CHF 6.7 Mio or 33% of the SNSF funding total
granted for RCTs did not result in peer-reviewed publica-
tions.
Strengths and limitations
This is the first study assessing funding characteristics of
publicly funded RCTs in Switzerland. After signing ap-
propriate confidentiality statements, we had access to pro-
posals for all healthcare RCTs supported by the SNSF
without restriction by the funder or the applicants [14].
Methodologically trained reviewers systematically identi-
fied subsequent publications and extracted data indepen-
dently and in duplicate. We combined information from
several sources (grant proposals, trial registries, publica-
tions and investigator survey) in order to increase the accu-
racy of the data set.
Limitations of our study include data missing owing to the
low reporting quality of some older RCT proposals, in-
ability to extract individual RCT grant sums from com-
bined proposals, or lack of response of investigators to our
survey. However, our overall response rate of 67% is still
sufficient to approximate average total cost per RCT and
in line with other similar studies surveying biomedical re-
searchers [15, 16]. Our comparison with the UK study had
not enough power for inferential statistical comparisons
because we restricted our sample to the same time period
as the UK study. We were not able to compare our results
with more recent data from the UK because more updated
funding characteristics were not available [17, 18]. Apart
from the multivariable logistic regression analysis in a pre-
vious publication [12], we did not further explore the rea-
sons for nonpublication.
Implications and conclusion
The SNSF is mandated by the Swiss Federal Government
and thus funded by the public. The SNSF invested CHF
6.7 million (not inflation-adjusted) in RCTs that were nev-
er published in peer-reviewed scientific journals. We were
not able to quantify the absolute amount of money spent
for these unpublished RCTs, including costs such as those
associated with ethical review process. We were not able to
elucidate how the money was spent in detail. We acknowl-
edge that even if an RCT were not published, its conduct
might have had positive and important consequences, such
as capacity building within a research group or develop-
ment of follow-up studies. However, the absence of results
from these SNSF-supported RCTs in peer-reviewed scien-
tific journals is worrisome. Nonpublication is not only a
waste of precious resources, but also compromises system-
atic reviews and meta-analyses, and undermines the pub-
lic’s and in particular the patients’ trust in clinical research
and motivation to participate. We found no evidence that
Table 2: Funding characteristics of randomised clinical trials supported by the Swiss National Science Foundation.
All (n = 101)Characteristic
SNSF grant proposal included one RCT only
(n = 74)
SNSF grant proposal included a RCT and other pro-
jects
(n = 27)
Estimation of total RCT costs,
median, CHF (IQR)*
427 500 (282 000–900 000) 340 000 (235 000–575 000)
Total SNSF grant sum,
median, CHF (IQR)
221 969 (165 692–276 357) 288 000 (215 449–377 500)
Cost covered by SNSF grant sum,
median %, (IQR)†
67 (40–80) 60 (38–69)
SNSF grant sum per planned participant, median, CHF
(IQR)
1608 (573–3002) 5640 (2281–8781)‡
Additional funding mentioned
Yes, n (%) 52 (70) 19 (70)
No, n (%) 9 (12) 0 (0)
Unclear, n (%) 13 (18) 8 (30)
Additional funding source§
Industry 15 7
In-house 20 6
Government¶ 8 2
Private 19 7
Medical societies** 8 8
IQR = interquartile range; RCT = randomised clinical trial; SNSF = Swiss National Science Foundation * 32 missing data due to missing survey answer (n = 69) † 28 missing data
due to missing survey answer (n = 73) ‡ 1 missing datapoint for planned sample size § Several answers possible ¶ Swiss Federal Office of Sports, Swiss Tobacco Prevention
Funds, etc. ** Swiss Heart Foundation, Swiss Multiple Sclerosis Society, Swiss Society of Pneumology, Swiss Lung League, etc.
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the proportion of unpublished RCTs has changed over the
last 20 years [12].
Public funding agencies should have a genuine interest in
ensuring that results, data and lessons learned from fund-
ed RCTs are made available to the scientific communi-
ty and that ultimately the public will benefit from them.
This can be achieved through dissemination of results or
sharing of data in data repositories or trial registries and
supporting initiatives such as AllTrials (www.alltrials.net).
Unfortunately, even after the ICMJE official recommenda-
tion to prospectively register all RCTs, only 77% were reg-
istered in a trial registry. Public funding agencies should
help endorse publication policies by making adherence to
standards of publication and data sharing a condition of
Table 3: Characteristics of randomised clinical trials supported by the Swiss National Science Foundation by publication status.*
All (n =
74)
Characteristic
Published as peer-reviewed
publication
(n = 39)
n (%)
Not published
(n = 26)
n (%)
Status unclear†
(n = 9)
n (%)
Age group of study population
Adults 34 (87) 23 (88) 8 (89)
Children <18yrs 3 (8) 3 (12) 0 (0)
Elderly >60yrs 2 (5) 0 (0) 1 (11)
Study population
Patients (suffering from disease or at risk for disease) 36 (92) 26 (100) 9 (100)
Healthy volunteers 3 (8) 0 (0) 0 (0)
Type of intervention
Behavioural intervention 13 (33) 11 (42) 2 (22)
Medication 10 (26) 6 (23) 6 (67)
Rehabilitation 4 (10) 5 (19) 0 (0)
Other‡ 7 (18) 1 (4) 1 (11)
Surgical 3 (8) 3 (12) 0 (0)
Diagnostic test 2 (5) 0 (0) 0 (0)
Clinical area
Anaesthetics 1 0 0
Angiology 1 0 0
Cardiovascular 6 4 2
Emergency medicine 0 1 1
Endocrinology 1 0 0
Gastrointestinal 1 0 0
General surgery 1 0 0
Infectious diseases 2 1 0
Intensive care 1 0 0
Medical education 2 0 0
Neonatology 1 0 0
Neurology 4 1 1
Neurosurgery 0 1 0
Obstetrics/gynaecology 1 1 2
Oncology 0 1 0
Ophthalmology 0 1 0
Physiotherapy 2 2 0
Pneumology 4 1 2
Psychiatry 7 8 1
Public health 2 2 0
Rehabilitation 1 0 0
Rheumatology 1 2 0
Planned sample size, median (IQR) 160 (100–545) 100 (66–233) 250 (240–420)
Planned centres
Single-centre 19 (49) 17 (65) 3 (33)
Multicentre national 16 (41) 6 (23) 3 (33)
Multicentre international 4 (10) 3 (12) 3 (33)
Trial registration
% of trials that started before 2005 and were registered 50% (6/12) 2% (2/10) n/a (0/0)
% of trials that started in/after 2005 and were registered 81% (22/27) 63% (10/16) 89% (8/9)
Gender of primary grant holder
Female 5 (13) 3 (12) 4 (44)
Male 34 (87) 23 (88) 5 (56)
* Only Swiss National Science Foundation grant proposals that included one randomised clinical trial only † Reported as follow-up still ongoing (n = 3) or manuscript still in prepa-
ration up to 5 years after end of study (n = 6) ‡ Includes randomised clinical trials testing a treatment algorithm or light therapy, etc.
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Table 4: Swiss National Science Foundation grant sum by publication status.*
Publication Status (n = 74) SNSF grant sum in CHF (% of total: CHF 20 477 189)
Published as peer-reviewed publication (n = 39) 9 098 006 (44)
Not published as peer-reviewed publication (n = 26) 6 710 090 (33)
Not published at all (n = 13) 2 782 621
Conference abstract only (n = 11) 2 376 750
Brief report or letter to editor only (n = 2) 1 550 719
Final publication status unclear† (n = 9) 4 669 093 (23)
* Only Swiss National Science Foundation grant proposals that included one randomised clinical trial only † Reported as follow-up still ongoing (n = 3) or manuscript still in prepa-
ration up to 5 years after end of study (n = 6)
Table 5: Comparison with UK trial cohort.
Characteristic SNSF-supported RCTs*
(n = 14)
MRC/HTA-supported RCTs
(n = 122)
Grant sum per participant, CHF, median (range) 1303 (143–10 000) 1452 (36-10 245)
Above UK threshold for sufficient funding†, n (%) 3 (21) 35 (29)
HTA = UK Health Technology Assessment programme; MRC = UK Medical Research Council; RCT = randomised clinical trial; SNSF = Swiss National Science Foundation * Only
SNSF grant proposals between 1994–2002 that included one RCT only † More than GBP 1000 or CHF 2270 per planned participant
transfer of funds to investigators on (for example, adher-
ence to a specific deadline after trial completion, such as
18 months, as suggested by the Institute of Medicine [19]).
The average grant sums per RCT spent by SNSF and
MRC/HTA programme between 1994 to 2002 were simi-
lar. McDonald et al. showed that 45% of the MRC/HTA-
supported RCTs failed to recruit 80% of the target sample
size and hence were at risk for premature discontinuation
[10]. The proportion of MRC/HTA-supported RCTs failing
to recruit 80% of their target decreased in the period be-
tween 2002 and 2008, but still accounted for 22% [17]. Re-
sults from our study were similar, in that one out of four
SNSF-supported RCTs were prematurely discontinued be-
cause of slow recruitment of study participants [12]. Since
adequate funding is a crucial factor to support recruitment,
one could hypothesise that in both Switzerland and the UK
the grant sums provided by the main public funding bod-
ies for RCTs were not sufficient. The SNSF has acknowl-
edged the need to better fund RCTs and started a new fund-
ing track in 2015, called the Investigator Initiated Clinical
Trial (IICT) programme, which might lead to better pub-
lication outcomes. Apart from sufficient funding, realistic
projection of the target sample size and adequate planning
of the recruitment process seem to be the main drivers for
successful trial completion [20]. Other reasons for recruit-
ment problems related to the Swiss healthcare system have
recently been compiled by Briel et al. in a qualitative study
[21].
In conclusion, publicly funded RCTs in Switzerland that
were not published subsequently are common and used
about a third of the SNSF funding granted for RCTs over
the last three decades. Rigorous measures are necessary
to ensure successful recruitment and publication. The new
SNSF funding track for investigator-initiated RCTs aims to
improve the situation but has yet to be evaluated.
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Appendix 1
Search algorithm for Swiss National Science
Foundation p3 research database
We searched titles and abstracts provided on the research
project database of the SNSF (p3 research database,
p3.snf.ch) for human healthcare RCTs using the “advanced
search” option and the following key words: random* OR
trial OR Zufallsprinzip.
We limited the results to the subject category “Biology and
Medicine” and “Health” (under “Humanities and Social
Sciences / Sociology”) and chose all “Funding Scheme”
except “r4d – Ecosystems”, “r4d - Employment”, “r4d –
Food Security”, “r4d - Open Call 1”, “r4d - Social Con-
flicts”, “Infrastructure”, “Science communication”. No
further search restrictions were applied.
Original article Swiss Med Wkly. 2018;148:w14587
Swiss Medical Weekly · PDF of the online version · www.smw.ch
Published under the copyright license “Attribution – Non-Commercial – No Derivatives 4.0”.
No commercial reuse without permission. See http://emh.ch/en/services/permissions.html.
Page 9 of 9
